Laboratory of Nutrition Chemistry, Department of Bioscience and Biotechnology, Faculty of Agriculture, Graduate School of Kyushu University, 6-10-1 Hakozaki, Higashi-ku, Fukuoka 812-8581, Japan.
Lipids Health Dis. 2014 Feb 19;13:36. doi: 10.1186/1476-511X-13-36.
Lactobacillus gasseri SBT2055 (LG2055) inhibits dietary fat absorption in rats and exerts preventive effects on abdominal adiposity in rats and humans. The present study aimed to evaluate the effects of LG2055 on postprandial serum lipid responses in Japanese subjects with hypertriacylglycerolemia after the intake of oral fat-loading test (OFLT) meals.
We conducted a single-blind, placebo-controlled, within-subject, repeated-measure intervention trial. Twenty subjects initially ingested the fermented milk (FM) without LG2055 for 4 weeks (control FM period), followed by a 4-week washout period, and then consumed FM containing LG2055 for 4 weeks (active FM period). The subjects were asked to consume FM at 200 g/day. At the end of each 4-week period, an 8-h OFLT was conducted. Blood samples were collected at fasting and every hour for 8 h after OFLT meal intake. Thereafter, postprandial serum non-esterified fatty acid (NEFA) and triacylglycerol (TAG) levels and fasting blood parameters were measured.
The OFLT showed that the postprandial serum NEFA levels from 120 to 480 min and the postprandial serum TAG level at 120 min in the active FM period were significantly (P < 0.05) lower than those in the control FM period. The fasting serum NEFA level in the active FM period significantly (P < 0.001) decreased at week 4 from the initial period compared with the control FM period.
The consumption of probiotic LG2055 reduced postprandial and fasting serum NEFA levels, suggesting its possible contribution to the reduction of the risk for obesity and type 2 diabetes mellitus.
UMIN000011605.
干酪乳杆菌 SBT2055（LG2055）可抑制大鼠的膳食脂肪吸收，并对大鼠和人类的腹部肥胖产生预防作用。本研究旨在评估 LG2055 对口服脂肪负荷试验（OFLT）餐后高甘油三酯血症日本受试者餐后血清脂质反应的影响。
我们进行了一项单盲、安慰剂对照、自身对照、重复测量的干预试验。20 名受试者最初摄入不含 LG2055 的发酵乳（FM）4 周（对照 FM 期），然后进行 4 周洗脱期，然后再摄入含有 LG2055 的 FM4 周（活性 FM 期）。要求受试者每天摄入 200 g FM。在每个 4 周期间结束时，进行 8 小时的 OFLT。在 OFLT 餐后摄入的 0、1、2、3、4、5、6、7、8 小时采集血样。此后，测量餐后血清非酯化脂肪酸（NEFA）和三酰甘油（TAG）水平以及空腹血液参数。
OFLT 显示，在活性 FM 期，120 至 480 分钟的餐后血清 NEFA 水平和 120 分钟的餐后血清 TAG 水平显著（P < 0.05）低于对照 FM 期。在活性 FM 期，与对照 FM 期相比，第 4 周时空腹血清 NEFA 水平显著（P < 0.001）降低。
食用益生菌 LG2055 可降低餐后和空腹血清 NEFA 水平，提示其可能有助于降低肥胖和 2 型糖尿病的风险。
UMIN000011605。
